177 related articles for article (PubMed ID: 34667217)
1. Upregulation of CD22 by Chidamide promotes CAR T cells functionality.
Yang X; Yu Q; Xu H; Zhou J
Sci Rep; 2021 Oct; 11(1):20637. PubMed ID: 34667217
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
Ramakrishna S; Highfill SL; Walsh Z; Nguyen SM; Lei H; Shern JF; Qin H; Kraft IL; Stetler-Stevenson M; Yuan CM; Hwang JD; Feng Y; Zhu Z; Dimitrov D; Shah NN; Fry TJ
Clin Cancer Res; 2019 Sep; 25(17):5329-5341. PubMed ID: 31110075
[TBL] [Abstract][Full Text] [Related]
3. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
[TBL] [Abstract][Full Text] [Related]
4. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
5. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
6. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Schultz LM; Jeyakumar N; Kramer AM; Sahaf B; Srinagesh H; Shiraz P; Agarwal N; Hamilton M; Erickson C; Jacobs A; Moon J; Baggott C; Arai S; Bharadwaj S; Johnston LJ; Liedtke M; Lowsky R; Meyer E; Negrin R; Rezvani A; Shizuru J; Sidana S; Egeler E; Mavroukakis S; Tunuguntla R; Gkitsas-Long N; Retherford A; Brown AK; Gramstrap-Petersen AL; Ibañez RM; Feldman SA; Miklos DB; Mackall CL; Davis KL; Frank M; Ramakrishna S; Muffly L
Leukemia; 2024 May; 38(5):963-968. PubMed ID: 38491306
[TBL] [Abstract][Full Text] [Related]
7. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
8. Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
Zeng W; Zhang Q; Zhu Y; Ou R; Peng L; Wang B; Shen H; Liu Z; Lu L; Zhang P; Liu S
Cancer Invest; 2022 Mar; 40(3):282-292. PubMed ID: 34797742
[TBL] [Abstract][Full Text] [Related]
9. A novel full-human CD22-CAR T cell therapy with potent activity against CD22
Tan Y; Cai H; Li C; Deng B; Song W; Ling Z; Hu G; Yang Y; Niu P; Meng G; Cheng W; Xu J; Duan J; Wang Z; Yu X; Feng X; Zhou J; Pan J
Blood Cancer J; 2021 Apr; 11(4):71. PubMed ID: 33839735
[No Abstract] [Full Text] [Related]
10. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ
J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.
Kokalaki E; Ma B; Ferrari M; Grothier T; Hazelton W; Manzoor S; Costu E; Taylor J; Bulek A; Srivastava S; Gannon I; Jha R; Gealy R; Stanczuk L; Rizou T; Robson M; El-Kholy M; Baldan V; Righi M; Sillibourne J; Thomas S; Onuoha S; Cordoba S; Pule M
Mol Ther; 2023 Jul; 31(7):2089-2104. PubMed ID: 36945773
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
13. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
14. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway.
Zhu M; Han Y; Gu T; Wang R; Si X; Kong D; Zhao P; Wang X; Li J; Zhai X; Yu Z; Lu H; Li J; Huang H; Qian P
Cell Rep; 2024 Apr; 43(4):114065. PubMed ID: 38578828
[TBL] [Abstract][Full Text] [Related]
15. Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.
Wang L; Zhang Y; Anderson E; Lamble A; Orentas RJ
Front Immunol; 2022; 13():825364. PubMed ID: 35222407
[TBL] [Abstract][Full Text] [Related]
16. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.
Shah NN; Qin H; Yates B; Su L; Shalabi H; Raffeld M; Ahlman MA; Stetler-Stevenson M; Yuan C; Guo S; Liu S; Hughes SH; Fry TJ; Wu X
Blood Adv; 2019 Aug; 3(15):2317-2322. PubMed ID: 31387880
[TBL] [Abstract][Full Text] [Related]
17. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
19. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
20. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
Jahn L; Hagedoorn RS; van der Steen DM; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(44):71536-71547. PubMed ID: 27689397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
